Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

$715K USD

Funder	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization	University of California Los Angeles
Country	United States
Start Date	Mar 21, 2022
End Date	May 02, 2023
Duration	407 days
Number of Grantees	2
Roles	Principal Investigator; Co-Investigator
Data Source	NIH (US)
Grant ID	`10594377`

Grant Description

Abstract This supplement will support ACTIV-2D ACTIV-2D is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with SARS-CoV-2 infection. The protocol is a phase III multicenter, randomized, double blind trial to evaluate the safety and efficacy of S-217622 for the treatment of symptomatic

high-risk non-hospitalized adults with SARS-CoV-2 infection. The primary outcome is to determine if the investigational agent (S-217622) will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study Day 29. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or

temporary facilities instituted to address medical needs of those with severe coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic.